Publication | Open Access

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

ThrombopoiesisAutoimmune DiseaseBlood PlateletPrimary Immune ThrombocytopeniaImmunologyClinical TrialsHematologyPlatelet AntagonistPharmacotherapyImmunotherapyMedicineAnticoagulantAdvance IvHealth Sciences